Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) CFO Sells 4,334 Shares of Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CFO Alethia Young sold 4,334 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $6.49, for a total transaction of $28,127.66. Following the sale, the chief financial officer owned 87,081 shares of the company’s stock, valued at $565,155.69. This trade represents a 4.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Alethia Young also recently made the following trade(s):

• On Friday, January 2nd, Alethia Young sold 3,289 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $6.80, for a total value of $22,365.20.

Bicycle Therapeutics Stock Performance

Shares of NASDAQ BCYC traded down $0.04 during trading hours on Tuesday, reaching $6.57. 259,093 shares of the stock were exchanged, compared to its average volume of 215,285. The firm has a market capitalization of $455.76 million, a price-to-earnings ratio of -1.81 and a beta of 1.52. The stock’s fifty day simple moving average is $6.97 and its 200 day simple moving average is $7.42. Bicycle Therapeutics PLC Sponsored ADR has a 52 week low of $6.03 and a 52 week high of $15.47.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.24. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%.The business had revenue of $11.73 million during the quarter, compared to the consensus estimate of $8.25 million. Research analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on BCYC shares. Citigroup restated an “outperform” rating on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Royal Bank Of Canada reissued a “sector perform” rating and issued a $11.00 price objective (down previously from $27.00) on shares of Bicycle Therapeutics in a report on Friday, October 31st. Truist Financial initiated coverage on shares of Bicycle Therapeutics in a research report on Monday, November 24th. They set a “hold” rating and a $10.00 target price on the stock. JMP Securities set a $12.00 price target on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Monday, December 22nd. Seven equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $19.73.

Hedge Funds Weigh In On Bicycle Therapeutics

Several hedge funds have recently bought and sold shares of BCYC. Assetmark Inc. lifted its holdings in shares of Bicycle Therapeutics by 74.9% during the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after acquiring an additional 1,552 shares during the period. The Manufacturers Life Insurance Company increased its stake in Bicycle Therapeutics by 1.6% in the second quarter. The Manufacturers Life Insurance Company now owns 140,492 shares of the company’s stock valued at $976,000 after acquiring an additional 2,243 shares during the last quarter. Virtus Investment Advisers LLC raised its position in Bicycle Therapeutics by 32.6% during the second quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock valued at $75,000 after purchasing an additional 2,659 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in Bicycle Therapeutics by 21.7% during the third quarter. Ameriprise Financial Inc. now owns 14,972 shares of the company’s stock worth $116,000 after purchasing an additional 2,668 shares during the last quarter. Finally, Ausdal Financial Partners Inc. bought a new stake in Bicycle Therapeutics during the second quarter worth $70,000. 86.15% of the stock is owned by institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.